Inpatient burden of gastric cancer in the United States

Solanki, Shantanu; Chakinala, Raja Chandra; Haq, Khwaja F.; Khan, Muhammad Ali; Kifayat, Alina; Linder, Katherine; Khan, Zubair; Mansuri, Uvesh; Haq, Khwaja S.; Nabors, Christopher; Aronow, Wilbert S.

doi:10.21037/atm.2019.11.54

Cited by 25 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results also showed that the cytoplasmic HuR was strongly decreased due to 5-FU, which indicates a negative regulatory role of HuR in gastric cancer. Conversely, in a previous study, HuR expression levels were reported to be significantly enhanced upon 5-FU stimulation in breast cancer cells (2). 5-FU induces the cytoplasmic export of HuR in pancreatic cancer (30).…”

Section: Discussionmentioning

confidence: 64%

5-FU blocks shuttling of HuR mediated by PKCδ in gastric cancer cells

Wu¹,

Xu²,

Guan³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: 5-fluorouracil (5-FU) is a common chemotherapy drug for gastric cancer. Human antigen R (HuR) is an RNA-binding protein that is also known as ELAV like RNA binding protein 1 (ELAVL1) regulates gene expression by binding to target genes 3' UTR region and is highly expressed in tumor tissues.However, the regulatory mechanisms of HuR in 5-FU mediated chemotherapy in stomach cancer are not well understood. In this study, we aimed to investigate 5-FU regulated PKCδ expression and translocation of HuR in SGC cell lines.Methods: Using Cell viability assay to obtained IC50 doses when SGC cells were treated with 5-FU for 2 and 3 days. Western blot was used to detect the total protein content of HuR and PKCδ after treating with 20 mM 5-FU. Furthermore, after adding 20 mM 5-FU, knocking down PKCδ, HuR and using inhibitor Staurosporine respectively, the protein content of HuR in the cytoplasm were detected by Western blot and Immunofluorescence. MTT assay was used to verify the changes in cell proliferation after knockdown of HuR.Results: Using Cell viability assay, we obtained IC50 doses of 77 and 20 mM, respectively, when SGC cells were treated with 5-FU for 2 and 3 days. The total protein content of HuR and PKCδ in SGC cells treated with 20 mM 5-FU did not change. However, Western blot and Immunofluorescence detected that the protein content of HuR in the cytoplasm decreased with 20 mM 5-FU treatment. Staurosporine inhibits the nucleation of HuR and is an inhibitor of PKC. Consistently, the expression of HuR in cytoplasm declined while knockdown of PKCδ. And the proliferation of SGC cells decreased after knocking down the HuR.Conclusions: Our results showed that 5-FU blocked shuttling of HuR from the nucleus to the cytoplasm in SGC cells through PKCδ phosphorylation.

show abstract

Section: Discussionmentioning

confidence: 64%

5-FU blocks shuttling of HuR mediated by PKCδ in gastric cancer cells

Wu¹,

Xu²,

Guan³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…This reduces bias seen in studies which are confined to one hospital or region. 52 However, our analysis has some limitations. We could not differentiate the hospitalizations with a new diagnosis of paralytic ileus from the old hospitalizations.…”

Section: Discussionmentioning

confidence: 96%

Paralytic ileus in the United States: A cross-sectional study from the national inpatient sample

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction: Paralytic ileus is a common clinical condition leading to significant morbidity and mortality. Most studies to date have focused on postoperative ileus, a common but not exclusive cause of the condition. There are limited epidemiological data regarding the incidence and impact of paralytic ileus and its relationship to other clinical conditions. In this cross-sectional study, we analyzed national inpatient hospitalization trends, demographic variation, cost of care, length of stay, and mortality for paralytic ileus hospitalizations as a whole. Methods: The National Inpatient Sample database was used to identify all hospitalizations with the diagnosis of paralytic ileus (International Classification of Diseases, 9th Revision code 560.1) as primary or secondary diagnosis during the period from 2001 to 2011. Statistical analysis was performed using Cochran–Armitage trend test, Wilcoxon rank sum test, and Poisson regression. Results: In 2001, there were 362,561 hospitalizations with the diagnosis of paralytic ileus as compared to 470,110 in 2011 (p < 0.0001). The age group 65–79 years was most commonly affected by paralytic ileus throughout the study period. In-hospital all-cause mortality decreased from 6.03% in 2001 to 5.10% in 2011 (p < 0.0001). However, the average cost of care per hospitalization increased from US$19,739 in 2001 to US$26,198 in 2011 (adjusted for inflation, p < 0.0001). Conclusion: There was a significant rise in the number of hospitalizations of paralytic ileus with increased cost of care and reduced all-cause mortality.

show abstract

“…The data are compiled yearly and contain discharge information from over 1,200 hospitals located across the states [ 7 ]. The internal validity of the database is guaranteed by the annual data quality assessments, while comparisons with data sources like the American Hospital Association (AHA) Annual Survey of Hospitals, National Hospital Discharge Survey from the National Center for Health Statistics, and Medicare Provider and Analysis Review (MedPAR) inpatient data from the Centers for Medicare and Medicaid Services guarantee the external validity [ 8 ].…”

Section: Methodsmentioning

confidence: 99%

“…We used the Cochran-Armitage trend test to calculate the trends for categorical variables and Wilcoxon rank sum test to assess continuous variables. These methods have been used in previous NIS-based studies [ 8 , 10 , 11 ]. We used the multivariate logistic regression model to determine predictors of mortality.…”

Section: Methodsmentioning

confidence: 99%

Gastric Antral Vascular Ectasia: Trends of Hospitalizations, Biodemographic Characteristics, and Outcomes With Watermelon Stomach

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Gastric antral vascular ectasia (GAVE) syndrome is a rare but significant cause of acute or chronic gastrointestinal (GI) bleeding, particularly in the elderly. The primary objective of this study was to determine the biodemographic characteristics, adverse outcomes, and the impact of GAVE hospitalizations on the US healthcare system.Methods: This retrospective database cross-sectional study used the National Inpatient Sample (NIS) from 2001 to 2011 to identify all adult hospitalizations with a primary discharge diagnosis of GAVE, with and without hemorrhage, using the International Classification of Diseases, Ninth Revision (ICD-9) codes. Individuals less than 17 years of age were excluded from the study. The outcomes included biodemographic characteristics, comorbidity measures, and inpatient mortality and the burden of the disease on the US healthcare system in terms of healthcare cost and utilization.

show abstract

Inpatient burden of gastric cancer in the United States

Cited by 25 publications

References 43 publications

5-FU blocks shuttling of HuR mediated by PKCδ in gastric cancer cells

5-FU blocks shuttling of HuR mediated by PKCδ in gastric cancer cells

Paralytic ileus in the United States: A cross-sectional study from the national inpatient sample

Gastric Antral Vascular Ectasia: Trends of Hospitalizations, Biodemographic Characteristics, and Outcomes With Watermelon Stomach

Contact Info

Product

Resources

About